Lady Gaga Reveals New Fibromyalgia Treatment That Changed Her Life
Health | By Olivia Bennett | March 30, 2026

Lady Gaga is opening up about a breakthrough in her ongoing battle with fibromyalgia, telling fans and followers that a new combination therapy has dramatically reduced her chronic pain and allowed her to perform at a level she feared she might never reach again. The 40-year-old singer and actress shared the update during a candid conversation on her podcast "Gaga Radio," where she spoke for nearly an hour about her health journey.
The Grammy and Oscar winner, who has been public about her fibromyalgia diagnosis since 2017, said she began a new treatment protocol last year that combines low-dose naltrexone with a specialized form of physical therapy and neurofeedback. "For the first time in almost a decade, I have more good days than bad days," Gaga said, audibly emotional. "I can rehearse for three hours without collapsing. I can play a show and not spend the next two days in bed. I feel like I got a piece of my life back."
Gaga was careful to note that her experience is personal and that fibromyalgia manifests differently in every patient. But she expressed hope that sharing her story would encourage others to explore emerging treatment options and not give up. "I've been to so many doctors, tried so many things that didn't work," she said. "If I had given up after the tenth failed treatment, I wouldn't be where I am today. Keep advocating for yourself."
The revelation comes as Gaga prepares for a 2026 world tour in support of her upcoming seventh studio album, her first full tour in several years. Sources close to the singer say the show has been designed with her health in mind, incorporating longer breaks between numbers and a rotating stage that reduces the physical demands of performance. Fibromyalgia advocacy organizations have reported a significant spike in website traffic and hotline calls since Gaga's podcast episode aired, underscoring the power of celebrity health disclosures to drive awareness.